glp-1 incretin effect A pathophysiological update of the incretins Incretins role in metabolic homeostasis

Broader metabolic balance

This is where it pays to read the fine print

A randomised controlled trial published in 2022 examined exenatide in individuals with AUD, finding no significant overall difference in alcohol consumption compared to placebo over a 26-week period, though a predefined subgroup analysis showed potential benefit specifically in participants with obesity

It remains the most consistent performer while your body calibrates to the medication

In that matched cohort, GLP-1 receptor agonist use was associated with a lower hazard of all-cause mortality, with a reported hazard ratio of 0.09, and a lower hazard of recurrence-free survival events, with a hazard ratio of 0.33 in unadjusted analyses

You also get access to group sessions, and Fridays users regularly note how meaningful the community support feels